18F-FDG PET may provide a quantitative measure to detect progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD), and could offer a mechanism to streamline clinical trials, according to a study published in this month's Journal of Nuclear Medicine.

Bioxydyn is developing an MRI tool to provide non-invasive regional assessments of lung ventilation/perfusion ratio and measures of changes in pulmonary vascular function.